Global Information
회사소개 | 문의 | 비교리스트

세계의 ALK 억제제 시장(2020-2024년)

Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2020-2024

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2020년 06월 상품 코드 943477
페이지 정보 영문 120 Pages
가격
US $ 2,500 ₩ 2,815,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,378,000 PDF (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,505,000 PDF (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,631,000 PDF (Global License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 ALK 억제제 시장(2020-2024년) Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2020-2024
발행일 : 2020년 06월 페이지 정보 : 영문 120 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 ALK 억제제 시장은 2020-2024년간 20%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 규모가 29억 6,000만 달러 확대될 전망입니다.

세계의 ALK 억제제 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 저해요인 분석, 유형별·지역별 시장 규모 추이 및 예측, 벤더 분석, 시장 기회 등의 종합적인 정보를 전해드립니다.

목차

개요

시장 상황

시장 규모

  • 시장의 정의
  • 시장 부문 분석
  • 시장 규모(2019년)
  • 시장 전망 : 예측(2019-2024년)

Five Forces 분석

유형별 시장 세분화

  • 시장 부문
  • 유형별 비교
  • 2세대 ALK 억제제 - 시장 규모 예측(2019-2024년)
  • 1세대 ALK 억제제 - 시장 규모 예측(2019-2024년)
  • 3세대 ALK 억제제 - 시장 규모 예측(2019-2024년)
  • 유형별 시장 기회

고객 상황

지역별 상황

  • 지역별 세분화
  • 지역별 비교
  • 북미 - 시장 규모 예측(2019-2024년)
  • 유럽 - 시장 규모 예측(2019-2024년)
  • 아시아 - 시장 규모 예측(2019-2024년)
  • 기타 지역 - 시장 규모 예측(2019-2024년)
  • 주요 국가
  • 지역별 시장 기회
  • 성장요인 - 수요
  • 성장요인 - 외부 요인
  • 시장의 과제
  • 시장 동향

벤더 상황

  • 개요
  • 벤더 상황
  • 파괴적 혁신

벤더 분석

  • 대상 벤더
  • 벤더의 시장 포지셔닝
  • AstraZeneca Plc
  • Betta Pharmaceuticals Co. Ltd.
  • Bio-Techne Corp.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Turning Point Therapeutics Inc.

부록

LSH 20.07.07

Technavio has been monitoring the anaplastic lymphoma kinase (ALK) inhibitors market and it is poised to grow by $ 2.96 bn during 2020-2024 progressing at a CAGR of 20% during the forecast period. Our reports on anaplastic lymphoma kinase (ALK) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high target affinity and specificity of ALK inhibitors and high prevalence of lung cancer. In addition, high target affinity and specificity of ALK inhibitors is anticipated to boost the growth of the market as well.

The anaplastic lymphoma kinase (ALK) inhibitors market analysis includes type segment and geographical landscapes

Technavio's ‘ anaplastic lymphoma kinase (ALK) inhibitors market ’ is segmented as below:

By Type:

  • Second-generation ALK inhibitors
  • First-generation ALK inhibitors
  • Third-generation ALK inhibitors

By Geography: landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies by the presence of patient assistance programs as one of the prime reasons driving the anaplastic lymphoma kinase (ALK) inhibitors market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our anaplastic lymphoma kinase (ALK) inhibitors market covers the following areas:

  • Anaplastic lymphoma kinase (ALK) inhibitors market sizing
  • Anaplastic lymphoma kinase (ALK) inhibitors market forecast
  • Anaplastic lymphoma kinase (ALK) inhibitors market industry analysis"

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anaplastic lymphoma kinase (ALK) inhibitors market vendors that include AstraZeneca Plc, Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Turning Point Therapeutics Inc.. Also, the anaplastic lymphoma kinase (ALK) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Second-generation ALK inhibitors - Market size and forecast 2019-2024
  • First-generation ALK inhibitors - Market size and forecast 2019-2024
  • Third-generation ALK inhibitors - Market size and forecast 2019-2024
  • Market opportunity by Type

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume drivers - Demand led growth
  • Volume drivers - External factors
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AstraZeneca Plc
  • Betta Pharmaceuticals Co. Ltd.
  • Bio-Techne Corp.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Turning Point Therapeutics Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Type - Market share 2019-2024 (%)
  • 22: Comparison by Type
  • 23: Second-generation ALK inhibitors - Market size and forecast 2019-2024 ($ million)
  • 24: Second-generation ALK inhibitors - Year-over-year growth 2019-2024 (%)
  • 25: First-generation ALK inhibitors - Market size and forecast 2019-2024 ($ million)
  • 26: First-generation ALK inhibitors - Year-over-year growth 2019-2024 (%)
  • 27: Third-generation ALK inhibitors - Market size and forecast 2019-2024 ($ million)
  • 28: Third-generation ALK inhibitors - Year-over-year growth 2019-2024 (%)
  • 29: Market opportunity by Type
  • 30: Customer landscape
  • 31: Market share by geography 2019-2024 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2019-2024 ($ million)
  • 34: North America - Year-over-year growth 2019-2024 (%)
  • 35: Europe - Market size and forecast 2019-2024 ($ million)
  • 36: Europe - Year-over-year growth 2019-2024 (%)
  • 37: Asia - Market size and forecast 2019-2024 ($ million)
  • 38: Asia - Year-over-year growth 2019-2024 (%)
  • 39: ROW - Market size and forecast 2019-2024 ($ million)
  • 40: ROW - Year-over-year growth 2019-2024 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: AstraZeneca Plc - Overview
  • 50: AstraZeneca Plc - Product and service
  • 51: AstraZeneca Plc - Key offerings
  • 52: AstraZeneca Plc - Key customers
  • 53: AstraZeneca Plc - Segment focus
  • 54: Betta Pharmaceuticals Co. Ltd. - Overview
  • 55: Betta Pharmaceuticals Co. Ltd. - Product and service
  • 56: Betta Pharmaceuticals Co. Ltd. - Key offerings
  • 57: Betta Pharmaceuticals Co. Ltd. - Key customers
  • 58: Betta Pharmaceuticals Co. Ltd. - Segment focus
  • 59: Bio-Techne Corp. - Overview
  • 60: Bio-Techne Corp. - Business segments
  • 61: Bio-Techne Corp. - Key offerings
  • 62: Bio-Techne Corp. - Key customers
  • 63: Bio-Techne Corp. - Segment focus
  • 64: F. Hoffmann-La Roche Ltd. - Overview
  • 65: F. Hoffmann-La Roche Ltd. - Business segments
  • 66: F. Hoffmann-La Roche Ltd. - Key offerings
  • 67: F. Hoffmann-La Roche Ltd. - Key customers
  • 68: F. Hoffmann-La Roche Ltd. - Segment focus
  • 69: GlaxoSmithKline Plc - Overview
  • 70: GlaxoSmithKline Plc - Business segments
  • 71: GlaxoSmithKline Plc - Key offerings
  • 72: GlaxoSmithKline Plc - Key customers
  • 73: GlaxoSmithKline Plc - Segment focus
  • 74: Merck KGaA - Overview
  • 75: Merck KGaA - Business segments
  • 76: Merck KGaA - Key offerings
  • 77: Merck KGaA - Key customers
  • 78: Merck KGaA - Segment focus
  • 79: Novartis AG - Overview
  • 80: Novartis AG - Business segments
  • 81: Novartis AG - Key offerings
  • 82: Novartis AG - Key customers
  • 83: Novartis AG - Segment focus
  • 84: Pfizer Inc. - Overview
  • 85: Pfizer Inc. - Business segments
  • 86: Pfizer Inc. - Key offerings
  • 87: Pfizer Inc. - Key customers
  • 88: Pfizer Inc. - Segment focus
  • 89: Takeda Pharmaceutical Co. Ltd. - Overview
  • 90: Takeda Pharmaceutical Co. Ltd. - Product and service
  • 91: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 92: Takeda Pharmaceutical Co. Ltd. - Key customers
  • 93: Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 94: Turning Point Therapeutics Inc. - Overview
  • 95: Turning Point Therapeutics Inc. - Product and service
  • 96: Turning Point Therapeutics Inc. - Key offerings
  • 97: Turning Point Therapeutics Inc. - Key customers
  • 98: Turning Point Therapeutics Inc. - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations
Back to Top
전화 문의
F A Q